TRIDENT LIFELINE Financial Statement Analysis
|
||
|
The Revenues of TRIDENT LIFELINE have increased by 45.59% YoY .
The Earnings Per Share (EPS) of TRIDENT LIFELINE has increased by 6.09 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
TRIDENT LIFELINE Last 5 Annual Financial Results
[BOM: 543616]
| Consolidated | Mar2023 | Mar2022 |
|---|---|---|
| Revenues | ₹32 Cr | ₹22 Cr |
| Expenses | ₹25 Cr | ₹19 Cr |
| Operating Profit (Excl OI) | ₹6.27 Cr | ₹2.71 Cr |
| Other Income | ₹1.16 Cr | ₹0.60 Cr |
| Interest | ₹0.48 Cr | ₹0.13 Cr |
| Depreciation | ₹0.37 Cr | ₹0.20 Cr |
| Profit Before Tax | ₹6.58 Cr | ₹2.98 Cr |
| Profit After Tax | ₹6.02 Cr | ₹3.95 Cr |
| Consolidated Net Profit | ₹6.02 Cr | ₹3.95 Cr |
| Earnings Per Share (Rs) | ₹5.23 | ₹4.93 |
| PAT Margin (%) | 18.98 | 18.14 |
| ROE(%) | 24.05 | 83.23 |
| ROCE(%) | 24.32 | 43.21 |
| Total Debt/Equity(x) | 0.12 | 0.52 |
Key Financials |
||
| Market Cap | : | ₹ 194.4 Cr |
| Revenue (TTM) | : | ₹ 32.5 Cr |
| Net Profit(TTM) | : | ₹ 6.1 Cr |
| EPS (TTM) | : | ₹ 5.3 |
| P/E (TTM) | : | 31.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| TRIDENT LIFELINE | -4.5% | 5.6% | 14.4% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.9% | 0.9% | 62.6% |
| CIPLA | 3.5% | 4.2% | 51.8% |
| DR REDDYS LABORATORIES | -1% | -2.4% | 28.4% |
| ZYDUS LIFESCIENCES | 12.2% | 18% | 103.8% |
| DIVIS LABORATORIES | 0.8% | 5.6% | 19.3% |
| MANKIND PHARMA | -6.1% | -11.9% | 54.1% |
| TORRENT PHARMACEUTICALS | 2.9% | 6.2% | 66.2% |
| LUPIN | 1.5% | 4.2% | 109.2% |
TRIDENT LIFELINE Revenues
[BOM: 543616]
| Y-o-Y | 45.59 % |
| 5 Yr CAGR | 45.59 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹32 Cr | 45.59 | |
| Mar2022 | ₹22 Cr | - | |
TRIDENT LIFELINE Operating Profit
[BOM: 543616]
| Y-o-Y | 131.30 % |
| 5 Yr CAGR | 131.30 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹6.27 Cr | 131.30 | |
| Mar2022 | ₹2.71 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 58.92 % |
| 5 Yr CAGR | 58.92 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 19.77% | 58.92 | |
| Mar2022 | 12.44% | - | |
TRIDENT LIFELINE Profit After Tax
[BOM: 543616]
| Y-o-Y | 52.36 % |
| 5 Yr CAGR | 52.36 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹6.02 Cr | 52.36 | |
| Mar2022 | ₹3.95 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 4.63 % |
| 5 Yr CAGR | 4.63 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 18.98 % | 4.63 | |
| Mar2022 | 18.14 % | - | |
TRIDENT LIFELINE Earnings Per Share (EPS)
[BOM: 543616]
| Y-o-Y | 6.09 % |
| 5 Yr CAGR | 6.09 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹5.23 | 6.09 | |
| Mar2022 | ₹4.93 | - | |
TRIDENT LIFELINE Return on Capital Employed (ROCE)
[BOM: 543616]
| Y-o-Y | -43.72 % |
| 5 Yr CAGR | -43.72 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 24.32% | -43.72 | |
| Mar2022 | 43.21% | - | |
TRIDENT LIFELINE Share Price vs Sensex
| Current Share Price | : | ₹169.0 |
| Current MarketCap | : | ₹ 194.4 Cr |
| Updated EOD on | : | May 18,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| TRIDENT LIFELINE | -4.5% |
5.6% |
14.4% |
| SENSEX | 1.7% |
1.5% |
18.7% |
TRIDENT LIFELINE related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about TRIDENT LIFELINE Financials
How the annual revenues of TRIDENT LIFELINE have changed ?
The Revenues of TRIDENT LIFELINE have increased by 45.59% YoY .
How the Earnings per Share (EPS) of TRIDENT LIFELINE have changed?
The Earnings Per Share (EPS) of TRIDENT LIFELINE has increased by 6.09 % YoY .
Check out Intrinsic Value of Peers of TRIDENT LIFELINE
Compare Stock Analytics of Peers of TRIDENT LIFELINE
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
